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Background: In this trial, our objective was to evaluate the relationship between long-term clinical 
outcomes in patients with peripheral arterial disease (PAD) treated with retrograde endovascular 
recanalization (ER) of chronic total occlusions (CTOs) regarding the infra-inguinal lower limb arteries and 
chronic obstructive pulmonary disease (COPD).
Methods: A total of 834 consecutive subjects were enrolled in the study. The mean age was 67.8±10.6 years 
(62.6% males). COPD was diagnosed in 98 patients (11.7%). The infra-inguinal location included the deep, 
superficial and common femoral artery, popliteal artery or below the knee arteries. During follow-up, we 
evaluated major adverse cardiac and cerebrovascular events (MACCE) and major adverse limb events (MALE). 
MACCE was considered as death, stroke/transient ischemic attack, myocardial infarction, percutaneous 
coronary intervention or coronary artery bypass grafting operation, while MALE regarded amputation, 
target lesion re-intervention, target vessel re-intervention and surgical action.
Results: The mean follow-up was 1,144.9±664.3 days and the interquartile range was 1,110.5 (504.5–
1,734.7). Data were collected between 2006 and 2016. We noticed significant differences in death rates 
among the COPD and non-COPD groups. The cumulative number of events (deaths) was 12.2%, 17.3%, 
18.4%, 22.4%, 23.5%, 23.5% and 23.5% in the COPD group and 6.1%, 7.5%, 10.5%, 11.3%, 11.4% 11.5% 
and 11.5% in the non-COPD group after 1, 2, 3, 4, 5, 6 and 7 years of follow-up, and was notably greater for 
COPD (P=0.0007).
Conclusions: Patients with COPD and PAD treated with the ER and retrograde approach due to CTOs 
are related to higher mortality than non-COPD patients. 
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chronic obstructive pulmonary disease (COPD)
Submitted Aug 28, 2019. Accepted for publication Nov 11, 2019.
doi: 10.21037/atm.2020.01.57
View this article at: http://dx.doi.org/10.21037/atm.2020.01.57
206
Original Article
Ruzsa et al. Retrograde recanalization in PAD and COPD
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2020;8(5):206 | http://dx.doi.org/10.21037/atm.2020.01.57
Page 2 of 11
Introduction
The endovascular revascularization (ER) procedures 
applied for patients with peripheral artery disease (PAD) 
are constantly improving and have become more attainable 
throughout the years. ER is the action of choice in the most 
cases experiencing symptomatic PAD. In the case of patients 
diagnosed with chronic total occlusion (CTO) of the lower 
limb arteries and failure of ER with antegrade access, 
retrograde access is an option for treatment prior to referral 
to a vascular surgeon or possible optimal medical therapy 
(OMT). In many research papers, the long-term results of 
regular ER with the use of antegrade access in PAD patients 
are presented. These publications include comparisons 
of antegrade and retrograde access sites (1,2). Among 
predictors of clinical outcomes in these patients, the authors 
revealed such indices as c-reactive protein serum level, brain 
natriuretic peptide serum level, anemia, kidney failure, 
age, gender, diabetes or depression (3-9). Nonetheless, 
evaluation of predictors concerning long-term ER results 
among subjects experiencing PAD treated from retrograde 
access is less frequently described in the literature. This is 
mainly due to the low availability of large groups of subjects 
treated this way. This also applies to the consequences of 
chronic obstructive pulmonary disease (COPD) regarding 
ER results among the PAD group independently of vascular 
access. Data concerning those relationships are scarcely 
available in the literature. Studies on other groups of 
patients undergoing revascularization procedures including 
percutaneous interventions with atherosclerosis located in 
various vascular beds demonstrated statistically significantly 
higher adverse event rates for the COPD group in 
comparison with the non-COPD (10-13). COPD presence 
among PAD patients is itself associated with increased 
mortality (14). However, the group of patients with PAD 
and CTOs of the infra-inguinal arteries seems to be 
significantly different from those analyzed so far. CTOs of 
the infra-inguinal arteries are often associated with chronic 
and critical muscle ischemia of below-the-knee parts of 
muscle groups larger than average. Those patients are more 
often prone to necrotizing pro-inflammatory lesions. It can, 
therefore, be assumed that the increase of pro-inflammatory 
markers and other toxic substances for the body in blood 
exceeds the negative effect of COPD on the results of 
endovascular treatment in this group of patients during 
long-term follow-up. We wanted to estimate with which 
of the individual MACCE and MALE components the co-
existence of COPD has the greatest relationship.
Consequently, the objective of this study is assessment of 
the correlation for COPD and long-term clinical outcomes 
regarding ER of CTOs from retrograde entrée among PAD 
subjects, with special insight into survival analysis. 
Methods
Study population
This research project was organized as a prospective 
observational study of consecutive patients undergoing 
retrograde recanalization of CTO in the superficial 
femoral artery (SFA), popliteal artery (PA) or below-
the-knee arteries. At two experienced and collaborating 
centres, all consecutive patients were enrolled following 
a minimum of one ineffective antegrade recanalization of 
CTO eligible for the retrograde access method. Inability 
to perform antegrade was considered failure to wire the 
distal part of the vessel following occlusion via access site, 
found in the contralateral artery or proximal to the CTO 
lesion. The inability to wire the distal part of the CTO 
was caused by failure to penetrate the lesion or because 
of failure to return to the arterial lumen after subintimal 
recanalization in given cases with suitable anatomy and 
morphology of target lesions. Crossing devices and/or 
micro wires facilitating intraluminal penetration of CTOs 
were applied to a limited extent because of a notable rise 
the treatment expenses. Nonetheless, this had no influence 
on the results of statistical calculations. Consistent with the 
applicable modus operandi, patients underwent screening 
for concomitant illnesses, risk factors and medication before 
the treatment. Ankle-brachial index was examined and PAD 
severity was evaluated on the basis of the Rutherford and/or 
Fontaine scales for all participants prior to the procedure. 
The choice considering retrograde recanalization and 
access site was based on earlier performed angiography. 
The retrograde recanalization action was conducted under 
local anesthesia and demanded two access sites: antegrade 
and retrograde. Both proximal and distal punctures were 
conducted under the guidance of vascular ultrasound and/
or fluoroscopy. The choice of antegrade access site was 
influenced by various factors, among others, anatomical 
conditioning, type of vascular lesions (dissemination, 
calcifications, length), technical potential (having 
sufficiently long catheters), type of occlusions, its length 
and likelihood of blood flow restoration. In the case of 
the proximal access site, the contralateral femoral artery 
was utilised most frequently, and 6 Fr vascular sheaths 
were some of the most popular. The distal access site 
was typically selected for the artery’s reconnection area 
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(needle: 12–15 mm, 21G). In some situations, 4 Fr vascular 
sheaths were required to acquire support at the time of the 
procedure. In a couple of instances, the distal access site 
was additionally applied in the case of revascularization 
of the more peripheral artery fragments. The hydrophilic 
0.035'' (0.89 mm) guidewire was implemented for the 
antegrade access site. Occlusions were crossed from 
the retrograde access site using non-hydrophilic 0.018'' 
(0.46 mm) guidewires. After crossing the occlusion with 
a wire using the retrograde approach, we carried out 
pre-dilatation via a balloon catheter. Then, the operator 
decided whether or not to implant the stent. Following 
the procedure, the distal sheet was instantaneously taken 
out, while the proximal one was in place for a maximum of 
4 hours until puncturing of the femoral artery took place. 
This was modified via the usage of unfractionated heparin. 
Because of dissection, in a few instances, the inflation of the 
balloon was conducted from ante- and retrograde access 
(which is the kissing balloon technique) in order to tear 
the dissection and to facilitate capturing the wire via the 
diagnostic catheter. The first antegrade puncture site was 
used to visualize the vessel at the time of the retrograde 
access procedure, antegrade puncture site one was utilized 
for vessel visualization. This was distinguished as the first 
access site for angiography. In a number of the patients, 
because of anatomically-, morphologically- or technically-
related issues, it was impossible to access the artery’s distal 
part being treated via retrograde access for angiography. 
These patients were forced to undergo puncturing of a 
different artery—considered the second, third or fourth 
antegrade site for angiography access. For periprocedural 
management, all patients underwent double antiplatelet 
treatment: aspirin 75 mg—permanently, and clopidogrel 
75 mg for a 3-month period, high level dosages of statin and, 
in accordance with the applicable practice, low-molecular-
weight heparin for a 4-week period. Supplementary 
treatment was in applied according to individual risk 
factors as well as deaths. COPD was defined according 
to the current international guidelines by the presence of 
irreversible airflow obstruction [post-bronchodilator first 
second expiratory volume (FEV1)/forced vital capacity (FVC) 
<0.70] and corrected according to age-related cut-off values 
not higher than the lower fifth percentile [lower limit of 
normal] of this quotient taken from the general population) 
and was confirmed by the treating specialist of respiratory 
diseases. This was verified by spirometry in each case (10). In 
the long-term follow-up, which lasted 1,144.9±664.3 days, 
the patients underwent evaluation regarding major adverse 
cardiac as well as cerebrovascular events (MACCE), major 
adverse limb events (MALE). The data were accumulated 
during the 2006–2016 period. In the case of this study, 
MACCE were pre-established as comorbidity, stroke/TIA, 
myocardial infarction, percutaneous coronary intervention 
(PCI) or coronary artery bypass grafting (CABG). MALE 
was considered as amputation, target vessel re-intervention, 
target lesion re-intervention as well as surgical treatments. 
Because of deficiencies in accessible sources, the amputation 
level was not emphasized in this work, and alike high-, 
mid- and low-amputations, they were part of the concept 
regarding the total rate of amputations. The protocol was in 
accordance with the 1964 Declaration of Helsinki, and all 
of the participants gave their informed and written consent 
to take part in the trial. Due to the fact that the data in the 
study were collected retrospectively, the consent of the 
Bioethics Committee was not required.
Statistical analysis
Categorical variables are demonstrated as numbers and 
proportions, while the continuous ones are presented 
as means (standard deviation, SD) or median as well as 
interquartile range. The variable characterization was 
determined via normality with the Shapiro-Wilk test. 
Variance equality was analyzed via the test by Levene’s. 
Inter-group disripancies were subjected to comparison 
the Student’s or Welch’s t-tests, which was dependent on 
variance equality for those variables that were characterized 
by normal distribution. The Mann-Whitney U-test was 
applied for continuous variables characterized by non-
normal distribution. Comparison of categorical variables 
was done with the chi-squared test by Pearson or using 
Fisher’s exact test when 20% of the cells had the anticipated 
count below five. The Cochrane-Armitage trend test was 
applied to compare the ordinal variables. For analysis 
of survival-rate among selected groups under risk, we 
performed computations of Kaplan-Meier curves. The log-
rank statistic test was implemented to determine differences 
in the results for particular groups. All of the performed 
statistical analyses were conducted via JMP®, Version 13.1.0 
(SAS Institute INC., Cary, NC, USA). A P value below 0.05 
was considered to be of statistical significance. The size 
of the sample was not counted because the reported work 
was based on the database registry, the original purpose of 
which was not to assess the impact of COPD on mortality. 
All analyzes were calculated lesion-based. In the case of 
bilateral involvement, one limb was included in the analysis 
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and this was recognized as one ER, which in some cases, 
could be multi-segmental. The treated lesion concerned the 
limb which was clinically more affected by ischemia.
Patient participation
None of the studied patients had any direct involvement in 
posing the research questions, the choice of the outcome 
means, the research plan, its execution, or in result 
interpretation.
Results 
General description
In total, the study comprised 834 patients. There were 
736 participants (58.3% males) in the non-COPD group 
and 98 subjects (78.6% males) within the COPD group. 
The mean age did not differ significantly between both 
investigated groups 68.1±10.7 and 68.6±11.2 years, 
respectively (P=0.6). Diabetes occurred more often in the 
non-COPD group compared to COPD (52.8% vs. 37.8%; 
P=0.005), while concomitant coronary artery disease (49.0% 
vs. 32.3%; P=0.001), prior percutaneous transluminal 
angioplasty (PTA) (32.0% vs. 19.0%; P=0.001) and the 
bypass surgical procedure (18.4% vs. 9.7%; P=0.008) 
occurred significantly more often in the COPD group. In 
the comparison of the COPD and non-COPD groups, the 
Table 1 General characteristics, clinical presentation and 
biochemical indices
Variables
Non-COPD 
(n=736)
COPD 
(n=98)
P value
Age, years 68.1±10.7 68.6±11.2 0.6U
Male gender, % 58.3 78.6 <0.001P
Body mass index, kg/m2 27.4±5.4 26.2±5.5 0.2U
Hypertension, % 88.8 88.8 0.98P
Diabetes, % 52.8 37.8 0.005P
Renal failure, % 16.0 17.3 0.74P
Coronary artery disease, % 32.3 49.0 0.001P
Stroke/transient ischemic 
attack, %
8.7 7.1 0.6P
Smoking, % 59.4 75.8 0.07P
Prior PTA, % 19.0 32.0 0.001P
Prior bypass surgery, % 9.7 18.4 0.008P
Biochemical indices
Hemoglobin, g/dL 13.6±1.6 14.2±1.3 0.45S
Platelet count, ×1,000/µL 240.9±69.1 218.7±71.6 0.59S
Creatinine, µmol/L 88.4±47.6 81±12.2 0.65U
eGFR, mL/min/1.73 m2 54.8±11.8 60±12.4 0.26U
Clinical presentation before angioplasty
Rutherford classification 
(15), %
0.87CA
0 0 0
1 2.6 4.3
2 16.1 13.0
3 13.9 9.8
4 17.9 26.1
5 16.5 13.0
6 33.0 33.8
Fontaine scale (16), % 0.82CA
2a 2.7 4.3
2b 31.2 22.8
3 16.8 26.1
4 49.3 46.8
Table 1 (continued)
Table 1 (continued)
Variables
Non-COPD 
(n=736)
COPD 
(n=98)
P value
Wagner scale (17), % 0.23CA
0 4.6 0
1 13.7 12.5
2 8.8 4.2
3 0.4 0
4 67.1 75.0
5 5.4 8.3
CA, Cochran-Armitage test for trend; eGFR, estimated glomerular 
filtration rate; P, Pearson’s chi-squared test; PTA, percutaneous 
transluminal angioplasty; S, Student’s t-test; U, Mann-Whitney U 
test; COPD, chronic obstructive pulmonary disease.
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difference in the percentage of smokers was not statistically 
significant (59.4% vs. 75.8%; P=0.07). There were no 
statistically significant differences between the mean serum 
creatinine (88.4±47.6 vs. 81±12.2 µmol/L; P=0.65) and 
hemoglobin (13.6±1.6 vs. 14.2±1.3 mg/dL, P=0.45) levels. 
Those and other indices are presented in Table 1. 
Clinical presentation
Acute limb ischemia was an indication for angioplasty more 
often in the COPD group (8.16% vs. 5.16%; P=0.22). 
Patients with acute ischemia constituted a significant 
minority of the whole and were mostly patients with chronic 
critical limb ischemia that had deteriorated. Patients were 
qualified for ER mainly due to their willingness to avoid 
surgical treatment and the potential for the successful 
endovascular procedure based on angiographic examination. 
Also, critical limb ischemia was more often an indication 
for angioplasty in the COPD group compared to non-
COPD (68.4% vs. 62.1%; P=0.22). While intermittent 
claudication was an indication for angioplasty more often in 
the non-COPD in comparison to the COPD group (32.6% 
vs. 24.5%; P=0.1). Other clinical scales illustrating clinical 
symptoms of PAD like Fontaine’s scale, the Rutherford 
classification and Wagner scale can be seen in Table 1. 
Indicators of angiography and the procedure 
In accordance with the classification proposed by the 
Trans-Atlantic Inter Society Consensus (TASC II), more 
disseminated atherosclerotic lesions were observed in 
the COPD in contrast to non-COPD (P=0.02). The 
concomitant significant stenosis of the iliac artery (20.4% 
vs. 11.5%; P=0.01) and the common femoral artery 
(CFA) (7.5% vs. 3.5%; P=0.16) before PTA was noticed 
more frequently for the COPD with regard to non-
COPD. Additionally, the average lesion length in the CFA 
(13.4±14.6 vs. 18.5±21.9 mm; P=0.1), SFA (124.5±108.9 vs. 
152.5±118.3 mm; P=0.02)  and PA (51.9±48.5 vs . 
55.4±49.6 mm; P=0.56) was longer in the COPD. The 
procedural success expressed as residual stenosis <40% 
estimated by angiography was achieved in 90.2% of patients 
from the COPD group, and for 86.7% of the subjects in 
the non-COPD (P=0.29). In contrast, procedure-related 
accomplishment presented as residual stenosis <30% was 
attained in 89.5% of subjects in the COPD and 83.7% of 
patients from the non-COPD (P=0.08). The total count of 
complications during the procedure was notably higher in 
the non-COPD group when weighed against the COPD 
(6% vs. 1%; P=0.04), the rate of major vascular complications 
was not statistically significantly higher in the COPD group 
compared to non-COPD (7.1% vs. 3.3%; P=0.08). Major 
vascular complications included, inter alia, the need for 
surgical intervention due to artery dissection and transfusion 
of blood substitutes. Intraprocedural complications covered, 
among others, allergic reactions or contrast-induced 
nephropathy. Minor vascular complications, which included 
mostly local bleeding treatable with local compression, 
occurred more often in the non-COPD vs. COPD group 
(13.5% vs. 9.2%, P=0.23). We noted only some cases of 
complications related to retrograde access, and they were 
mild bleeding complications from the puncture site or small 
hematomas. We did not notice arterio-venous fistulas as a 
complication of the retrograde access site. Hospitalization 
duration was considerably lengthier in the COPD compared 
to the non-COPD (7.44±7.44 vs. 5.22±4.95 days; P=0.008). 
Those and other angiographic and procedural indices are 
presented in Table 2.
Short-term results 
The total number of deaths within 30 days post-procedure 
totaled 3.06% in the COPD group and was 2.04% for 
the non-COPD group (P=0.5). Whereas the cumulative 
number of amputations within 30 days of follow-up was 
10.7% for the COPD and 8.7% in the case of non-COPD 
(P=0.5). 
Clinical endpoint
The follow-up lasted 84 months. During this time, 
endovascular re-interventions in lower limb arteries 
occurred not statistically significantly more often in the non-
COPD compared to the COPD group (36% vs. 27.5%; 
P=0.09). While the rates of myocardial infarctions (5.1% vs. 
2.9%; P=0.21), amputations (22.3% vs. 18.4%; P=0.35) and 
lower-limb bypass surgery (6.4% vs. 4.9%; P=0.61) were not 
viewed as having more statistical significance in the COPD 
versus non-COPD group. The only significant difference 
between both investigated groups was noticed for death rate, 
which was more than two times greater for the COPD in 
relation to the non-COPD (23.5% vs. 11.5%; P=0.001). The 
log-rank test confirmed statistically significant differences 
between those two groups (P=0.0007). This is presented in 
Figure 1 and Tables 3,4. In Table 5, the outcome of univariate 
Cox analysis can be found. Furthermore, multivariate 
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Table 2 Culprit artery, lesion and procedural indices
Selected indices Non-COPD COPD P value
TASC II (18), % 0.02CA
A 19.7 17
B 21.3 11
C 15.7 11
D 43.3 61
Angiography—first access 
site, %
0.01P
Brachial 3 8.2
Femoral 73 62.9
Radial 24 28.9
Angiography—number of 
access sites, %
0.21CA
1 82.3 76.5
2 16.2 21.4
3 1.2 2.1
4 0.3 0
Angiography—first access 
side, %
65.2 72.4 0.15P
Right
Left 34.8 27.6
Iliac artery—significant 
lesion, %
11.5 20.4 0.01P
Deep femoral artery—
significant lesion, %
4.8 6.1 0.61F
Common femoral artery 
Tortuosity 0.22F
Slight 5.6 1.5
No 94.4 98.5
Chronic total occlusion 3.5 7.5 0.16F
Calcification 0.93CA
No 46.4 46.3
Slight 37.8 38.8
Severe 15.8 14.9
Lesion length, mm 13.4±14.6 18.5±21.9 0.1U
Table 2 (continued)
Table 2 (continued)
Selected indices Non-COPD COPD P value
Superficial femoral artery 
Tortuosity 0.54CA
Severe 2.5 4.3
Slight 35.1 28
No 62.4 67.7
Chronic total occlusion 49.9 48.4 0.78P
Calcification 0.67CA
Extreme 3.3 2.1
Severe 43.8 41.9
Slight 35.3 38.7
No 17.6 17.3
Lesion length, mm 124.5±108.9 152.5±118.3 0.02U
Popliteal artery—lesion 
length, mm
51.9±48.5 55.4±49.6 0.56U
Lesion location in crural 
arteries, %
Tibio-fibular trunk 24.1 29.6 0.23P
Tibialis anterior artery 46 50 0.45P
Peroneal artery 35.8 42.3 0.21P
Tibialis posterior artery 47.4 48 0.91P
Fluoroscopy time, s 846.6±712.6 682.4±578.2 0.25U
Contrast volume, mL 119±83.6 134.6±90.5 0.11U
Time from procedure to 
discharge, days
3.63±2.31 2.25±0.5 0.33U
Hospitalization time, days 5.22±4.95 7.44±7.44 0.008U
Intraprocedural 
complications, %
6 1 0.04P
Major vascular 
complications, %
3.3 7.1 0.08F
Minor vascular 
complications, %
13.5 9.2 0.23P
CA, Cochran-Armitage test for trend; F, Fisher’s exact test; P, 
Pearson’s chi-squared test; TASC, Trans-Atlantic Inter Society 
Consensus; U, Mann-Whitney U test. 
Annals of Translational Medicine, Vol 8, No 5 March 2020 Page 7 of 11
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2020;8(5):206 | http://dx.doi.org/10.21037/atm.2020.01.57
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
0 365 730 1095 1460 1825
S
ur
vi
va
l p
ro
ba
bi
lit
y
Days
COPD
Non-COPD
P=0.007
Figure 1 The Kaplan-Meier curve for survival analysis regarding 
the COPD grouping variable. COPD, chronic obstructive 
pulmonary disease.
Table 3 The frequency of study endpoints and duration of follow-up according to the COPD status
Study endpoints and duration of follow-up Non-COPD COPD P value
Re-PTA (%) 265/736 (36.0) 27/98 (27.5) 0.09P
Days to Re-PTA 298.5±364.1 392.4±516.3 0.85U
Stroke/TIA (%) 20/736 (2.7) 3/98 (3.1) 0.74F
Days to stroke/TIA 363.9±396.5 778.3±675.8 0.23U
Myocardial infarction (%) 21/735 (2.9) 5/98 (5.1) 0.21F
Days to myocardial infarction 720.3±522.2 610.8±563.7 0.68S
Death (%) 85/736 (11.5) 23/98 (23.5) 0.001P
Days to death 498.6±467.7 510±479.7 0.83U
Amputation (%) 130/707 (18.4) 21/94 (22.3) 0.35P
Days to amputation 142.4±266.0 143.2±261.3 0.89U
Lower extremity bypass (%) 35/707 (4.9) 6/94 (6.4) 0.61F
Days to lower extremity bypass 264.4±303.1 133.3±237.3 0.19U
F, Fisher’s exact test; P, Pearson’s chi-squared test; PTA, percutaneous transluminal angioplasty; S, Student’s t-test; TIA, transient ischemic 
attacks; U, Mann-Whitney U test; COPD, chronic obstructive pulmonary disease.
Table 4 Cumulative risk of death according to COPD status (P=0.0007)
COPD 0 months 12 months 24 months 36 months 48 months 60 months 72 months 84 months
Yes
At risk 98 69 51 40 26 16 8 1
Cumulative number of events 0 12 17 18 22 23 23 23
No
At risk 736 588 448 316 216 128 32 3
Cumulative number of events 0 45 55 77 83 84 85 85
Total
At risk 834 657 499 356 242 144 40 4
Cumulative number of events 0 57 72 95 105 107 108 108
COPD, chronic obstructive pulmonary disease.
Cox analysis established a correlation of significance 
among COPD and death rate: hazard ratio (HR) and 95% 
confidence interval (CI) was 2.17 (1.34–3.38), P=0.0023. 
The overall study endpoints including MACCE and 
MALE did not differ significantly between COPD and 
non-COPD group (RR: 1.1, 95% CI: 0.84–1.46, P=0.45) 
during the follow-up stage. There were also no significant 
relationships for MALE (RR: 0.9, 95% CI: 0.66–1.24, 
P=0.54). However, there were significantly higher rates of 
MACCE in the COPD group compared to the non-COPD 
group (RR: 1.98, 95% CI: 1.3–3.02, P=0.0014). This was 
mostly caused by greater myocardial infarction, cerebral 
stroke/transient ischemic attack and death rates. Of these, 
mortality was the major difference.
Ruzsa et al. Retrograde recanalization in PAD and COPD
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2020;8(5):206 | http://dx.doi.org/10.21037/atm.2020.01.57
Page 8 of 11
Discussion
The key result of this study shows that PAD patients and 
those with diagnosed COPD prior to endovascular CTO 
treatment of the lower extremity infra-inguinal arteries 
are at a higher risk of death at the time of the long-term 
follow-up phase compared to the group of non-COPD 
patients. Numerous accessible research papers have shown 
MACCE and MAPE predictors during the follow-up in 
PAD patients treated with endovascular interventions. Since 
the first publication concerning the results of percutaneous 
angioplasty in PAD patients from a retrograde approach, 
the results of treatment have significantly improved (19). 
Nevertheless, there is still a lack of research among 
large populations approximating predictors of long-term 
management outcomes among this particular patient 
group, above all, in the case of subjects undergoing 
retrograde approach treatment. In this study, the death 
rate after 7 years of follow-up totaled 23.5% in the 
COPD group and 4.3% in among the non-COPD group, 
which was comparatively low in contrast to different and 
older papers in which the death rate for total group of 
PAD patients subjected to endovascular interventions 
amounted to 4.3–50%—comparable baseline mean age 
of the subjects participating in this trial, and dependent 
on follow-up duration (20-22). In their analysis, Bertelè 
et al. studied 1,560 patients at the mean age of 70.8 
(10.1) years with chronic/critical limb ischemia treated 
with different methods of revascularization. They reported 
mortality rates of 13.4% after 6 months and 19.1% after 
12 months. Greater mortality was related to older age, 
prior stroke, myocardial infarction and diabetes while 
prior revascularizations were related to lower death rate 
but higher amputation rate (20). Löfberg et al. presented a 
study on clinical outcomes in patients with femoropopliteal 
lesions and subcritical or critical lower limb ischemia. 
Their study included 98 patients and 121 PTAs (21). 
The early mortality (30 days) reached 4.3%. Kim et al. 
reported a mortality rate following the 12-month period 
of follow-up among patients with femoropopliteal disease 
(TASC C and D lesions) and treated with PTA on 5.5% (22). 
Whereas Kok et al. reported a mortality rate of 21% after a 
year-long follow-up in PAD patients treated for limb salvage. 
Mortality reached 50% after 5 years of follow-up (23). 
The study published previously by our team reported a 
1-year mortality rate at 5.8% among patients treated with 
retrograde vascular access with the mean follow-up at 
13.9 [4] months (24). This mortality was lower compared 
to our study, where after 12 months, this equaled 6.8% 
in the total group, 6.1% in the non-COPD and 12.2% 
in the COPD group. One of the main causes in which 
one can see the difference in mortality is related to 
age. The average age in our previous publication was 
5 years less. One of the few studies comparing the results 
of endovascular treatment of PAD from antegrade and 
retrograde access revealed comparable reintervention 
rates after the 5-year follow-up period and was decreased 
among subjects with retrograde puncture; however, without 
statistical significance (27.3% vs. 36%). Unfortunately, 
those studies did not deliver information on mortality 
rate (2). Another study assessing the effectiveness and 
clinical outcomes during the mean 17-month-long 
follow-up showed that the mortality rate in patients with 
critical limb ischemia and pedal vascular access was 23% 
during the mean follow-up period of 6 [4] months (25). 
In this case, an increased risk of mortality should be seen in 
a large percentage of patients with diabetes that was 76.9%. 
A systematic review including above 1,500 patients state a 
1-year survival rate among subjects treated using subintimal 
recanalization dependent on culprit artery location or 
symptoms prior to angioplasty. The rate was between 65% 
and 78% among patients with critical limb ischemia and 
crural lesion and was between 86% and 100% in patients 
with mixed-disease as well as femoral lesions (26). We may 
list prothrombotic state connected with COPD, increased 
pro-inflammatory and oxidative stress markers as some of 
the most significant mechanisms accountable for worse 
clinical outcome following lower limb artery PTA in the 
follow-up (27,28). The correlation between COPD and 
Table 5 The univariate Cox model for death depending on COPD
Outcome HR (95% CI) P value
Death 2.17 (1.34–3.38) 0.86
Stroke/TIA 1.11 (0.26–3.24) 0.002
Myocardial infarction 1.89 (0.63–4.68) 0.23
Re-PTA 0.73 (0.48–1.07) 0.11
Lower extremity bypass 1.30 (0.54–3.10) 0.54
Amputation 1.23 (0.74–1.92) 0.41
PTE/TEA 1.07 (0.06–6.03) 0.94
CI, confidence interval; HR, hazard ratio; PTA, percutaneous 
transluminal angioplasty; PTE, percutaneous thrombectomy; 
TEA, thromboendarterectomy; TIA, transient ischemic attack; 
COPD, chronic obstructive pulmonary disease.
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cardiovascular adverse events in the future among patients 
experiencing coronary artery disease has been presented 
on numerous occasions (29,30). In this study, a great 
patient percentage having coronary heart disease in the 
COPD group seem to be of great relevance, which can be 
connected with the higher occurrence rate of heart failure 
as well as various types of cardiac arrhythmia that may lead 
to sudden cardiac death. However, we do not have data 
on the incidence of heart failure or the causes of deaths in 
the follow-up period, which limits inference in this field. 
One of various factors, for which a strong correlation 
with endovascular outcome during the follow-up period 
can be found, is kidney failure. Kidney failure was viewed 
as a predictor of higher death rate after 4-year follow-
up among PAD patients subjected PTA. This was strictly 
associated with kidney-failure stage. The predicted 4-year 
mortality rate among patients with diagnosed kidney failure 
was 27%, however, in the case of patients with different 
stages, these values were 46% (stage 2), 52% (stage 3), 
72% (stage 4) and 78% (stage 5) (8). In the analyzed 
results of the present study, both the creatinine level and 
the percentage of patients with renal insufficiency was not 
significantly different concerning patients with or without 
COPD. Female gender was found to be associated with the 
increased death rate in selected subgroups of patients with 
cerebrovascular, coronary artery disease and black race. 
Those differences dissipated in octogenarians and patients 
with claudication (4). In the current study, the percentage 
of males was higher in the COPD group in comparison to 
the non-COPD. While the mortality rate was significantly 
higher in the COPD group. Thus, the increased rate 
of death was rather related to male than female gender. 
Also, diabetes is found to be an autonomous predictor of 
increased death rate among patients with PAD and critical 
limb ischemia treated with endovascular interventions (20). 
In the presented study, the percentage of patients with 
diabetes was higher in the non-COPD compared to COPD, 
and this was probably mostly owed to the higher percentage 
of females in this subgroup. However, in the current study, 
this factor seems to be not influential enough to modify the 
overall rate of mortality during follow-up.
Nevertheless, available publications have shown a 
number of factors related to the frequency of adverse 
events and vascular patency in the follow-up period. The 
culprit lesion length, a clinical state prior to angioplasty 
and the extent of atherosclerotic lesion distribution (TASC 
stage) can be found as some of the definite predictors of 
clinical outcome for PAD patients undergoing endovascular 
intervention treatment (21). This, at least in part, is reflected 
in our data, in which patients with significantly higher 
mortality from the COPD group had significantly higher 
rates of multi-segmental lesions expressed as TASC D 
stage or longer mean culprit lesion length. Also, other well-
known predictors of mortality during the follow-up period 
like diabetes, kidney failure or poor run off into the foot 
were found to predict graft failure in patients undergoing 
endovascular infra-inguinal revascularization (31). 
Recently published studies confirmed the relationship 
between COPD and smoking and clinical outcomes in 
patients with coronary artery diseases treated with PCI (32). 
Patients with COPD previously treated with PCI and 
smokers were at increased risk of in-stent thrombosis and 
restenosis. Additionally, COPD was found to be related 
to disseminated coronary atherosclerosis. More advanced 
and multi-segmental involvement of atherosclerosis found 
in patients with coronary artery disease and COPD was 
reflected in the current study, where TASC D lesions were 
significantly more frequently found in the COPD group 
as compared to the non-COPD. In the current study, 
concomitant COPD was not found to be a significant 
predictor of clinical outcomes other than mortality in 
patients with PAD treated with endovascular intervention 
from retrograde access. We noticed some variations 
regarding clinical outcome, nonetheless, they were not 
statistically significant. For example, re-PTA occurred more 
often in the non-COPD group, while myocardial infarction, 
amputation, and lower extremity bypass rate were more 
common among the COPD group when juxtaposed with 
non-COPD. A larger amount of re-PTAs for non-COPD 
patients may be the consequence of lower mortality and the 
associated possibility of such treatment.
Limitations
In this study, we may detect a number of limitations, one 
being the fact that we do not possess data on the etiology of 
deaths during the follow-up period and other concomitant 
diseases at baseline including heart failure or cardiac 
arrhythmias. In addition, we have no data on COPD, 
pneumonia or exacerbations of heart failure, which at this age, 
may be a potential cause of death for every hospitalization, 
apart from cardiological causes. There are also many other 
factors like sample size which may bring some bias to the 
present study. One of the most important is the coexistence 
of many comorbidities in the COPD group compared to 
patients without COPD at a much higher percentage, which 
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in itself, may decide about increased mortality.
Conclusions
Patients experiencing COPD as well as peripheral arterial 
disease concerning the infra-inguinal lower limb arteries 
undergoing endovascular recanalization of chronic total 
occlusions from retrograde access are related to the 
increased rate of deaths during follow-up. The results 
obtained in the presented study confirm the relationships 
observed in other groups of patients with atherosclerosis 
undergoing percutaneous procedures. Thus, it can be 
concluded that the impact of CTO and chronic, often 
critical, ischemia of large muscle groups could modify the 
effect of particular coexisting comorbidities and long-term 
clinical outcomes. The presence of COPD is associated 
with higher mortality, which may be a consequence of more 
advanced comorbidities, and the less frequent occurrence of 
re-PTA with a natural selection of patients more burdened 
with concomitant diseases. Therefore, the most appropriate 
approach in this group of patients, aimed at reducing 
mortality in the follow-up period, is multidisciplinary 
control of comorbidities and risk factors for atherosclerosis.
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